Cambridge, Massachusetts, United States The main department of described VC is located in the Cambridge. The venture was found in North America in United States.
We also calculated 3 valuable employees in our database.
The fund is generally included in 2-6 deals every year. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. Comparing to the other companies, this MRL Ventures Fund performs on 7 percentage points more the average number of lead investments. The top amount of exits for fund were in 2018. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The usual things for fund are deals in the range of 10 - 50 millions dollars.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Alector, Entrada Therapeutics, Carisma Therapeutics Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. Among the most successful fund investment fields, there are Health Care, Medical Device.
The standard case for the fund is to invest in rounds with 8-9 partakers. Despite the MRL Ventures Fund, startups are often financed by Atlas Venture, Amgen Ventures, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Atlas Venture, Amgen Ventures, SR One. In the next rounds fund is usually obtained by GV, Fidelity Management and Research Company, Atlas Venture.
Related Funds
Funds with similar focus
| Fund Name | Location |
| BnL Start Partners | Borsod-Abaúj-Zemplén, Hungary, Miskolc |
| Excalibur Partners | Delray Beach, Florida, United States |
| Gogin Capital | Japan, Matsue, Shimane Prefecture |
| Gorilla Private Equity | Seoul, Seoul-t'ukpyolsi, South Korea |
| Guoxuan Holdings | Anhui, China, Hefei |
| LearnLaunch Accelerator | Boston, Massachusetts, United States |
| NT Neue Technologie | Erfurt, Germany, Thuringia |
| Power Investment Holding | China, Hong Kong, Hong Kong Island |
| Qure Ventures | Herzliya, Israel, Tel Aviv |
| Rangoli Resorts | - |
| Richen Capital | China, Shanghai |
| SCOR Life & Health Ventures | - |
| Songtong Capital | China, Hangzhou, Zhejiang |
| Techstars Music | California, Los Angeles, United States |
| Tiny Super Computer Investment Company | Berlin, Berlin, Germany |
| Tospur Real Estate Consulting | China, Shanghai |
| Utao Investment | China, Minghang, Shanghai |
| WPS Office | California, Palo Alto, United States |
| Zhaopin | Beijing, Beijing, China |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
InduPro | $85M | 13 Jun 2024 | Seattle, Washington, United States | ||
Insamo | $12M | 21 Feb 2024 | Berkeley, California, United States | ||
Eyebiotech | $65M | 14 Nov 2023 | New York, New York, United States | ||
VectorY | $152M | 13 Nov 2023 | - | ||
Ray Therapeutics | $100M | 16 May 2023 | San Diego, California, United States | ||
Anavo Therapeutics | $10M | 02 May 2023 | Leiden, South Holland, Netherlands | ||
Therini Bio | $36M | 27 Apr 2023 | San Francisco, California, United States | ||
Carisma Therapeutics | $30M | 21 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
Photys Therapeutics | $75M | 08 Sep 2022 | Cambridge, Massachusetts, United States |
– Mozart Therapeutics, a Seattle-based biotech startup, raised $55m funding.
– The round was led by ARCH Venture Partners along with Sofinnova Partners.
– Other backers include MRL Ventures Fund from Merck, Leaps by Bayer, and Eli Lilly & Company.
– PAQ Therapeutics is a biotechnology company advancing a new approach to restoring health and curing disease through autophagy.
– The company announced the closing of a $30m Series A round.
– Sherpa Healthcare Partners led the round with participation from Huagai Capital, MSA Capital, and MRL Ventures Fund as well as seed investors Nest.Bio Ventures and Matrix Partners China.
– The funding will be used to advance the company’s ATTEC platform and progress its pipeline programs.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
InduPro | $85M | 13 Jun 2024 | Seattle, Washington, United States | ||
Insamo | $12M | 21 Feb 2024 | Berkeley, California, United States | ||
Eyebiotech | $65M | 14 Nov 2023 | New York, New York, United States | ||
VectorY | $152M | 13 Nov 2023 | - | ||
Ray Therapeutics | $100M | 16 May 2023 | San Diego, California, United States | ||
Anavo Therapeutics | $10M | 02 May 2023 | Leiden, South Holland, Netherlands | ||
Therini Bio | $36M | 27 Apr 2023 | San Francisco, California, United States | ||
Carisma Therapeutics | $30M | 21 Sep 2022 | Philadelphia, Pennsylvania, United States | ||
Photys Therapeutics | $75M | 08 Sep 2022 | Cambridge, Massachusetts, United States |
